The Journal of
Clinical Psychiatry

Neurology Dementia

Letter to the Editor July 15, 2003

Olanzapine/Risperidone and Diabetes Risk

David W. Lee, PhD ; Robert B. Fowler, BA

J Clin Psychiatry 2003;64(7):847-848

Article Abstract

Letter to the Editor

Olanzapine/Risperidone and Diabetes Risk.

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 86 • 2025 • Number 1

Read the Current Issue

Brief Report

Sex Differences in PTSD among US Military Veterans

Commentary

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Clinical and Practical Psychopharmacology

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Commentary

Evolving Care and Research Priorities in ADHD

Original Research

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Systematic Review

Efficacy and Safety of Memantine for Children and Adults with ADHD

View current Issue

Letter to the Editor

Why Ask Patients to Cut Into Quarters 10 mg THC Gummies From a Dispensary When 2.5 mg THC Is Available by Prescription?

June 5, 2024

The authors discuss a study by Sawicki et al of dementia patients for whom 2.5 mg of THC was recommended for neuropsychiatric symptoms.

Marina Goldman , Dimitri Markov

Letter to the Editor

THC Edible Gummies for Behavioral Symptoms of Dementia: Reply to Goldman and Markov

June 5, 2024

The authors reply to Goldman and Markov’s comments on their recent study of dispensary-obtained THC for dementia.

Erin K. Zahradnik , Cristian Hernandez

Letter to the Editor

Insights Into Poststroke Depression

August 31, 2023

The authors shed light on risk factors, purported mechanisms, diagnostic tips, and treatment options for poststroke depression.

Ahmed Naguy , Bibi Alamiri

Olanzapine/Risperidone and Diabetes Risk

Read the Current Issue

Sex Differences in PTSD among US Military Veterans

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Evolving Care and Research Priorities in ADHD

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Efficacy and Safety of Memantine for Children and Adults with ADHD

ELSEWHERE:

FOLLOW US:

Olanzapine/Risperidone and Diabetes Risk

Read the Current Issue

Sex Differences in PTSD among US Military Veterans

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Evolving Care and Research Priorities in ADHD

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Efficacy and Safety of Memantine for Children and Adults with ADHD

Related Articles

Why Ask Patients to Cut Into Quarters 10 mg THC Gummies From a Dispensary When 2.5 mg THC Is Available by Prescription?

THC Edible Gummies for Behavioral Symptoms of Dementia: Reply to Goldman and Markov

Insights Into Poststroke Depression

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles